McFarlane Neil F. 4
4 · ZEVRA THERAPEUTICS, INC. · Filed Feb 2, 2026
Research Summary
AI-generated summary of this filing
Zevra Therapeutics (ZVRA) CEO Neil McFarlane Sells 91,000 Shares
What Happened
Neil F. McFarlane, President, CEO and Director of Zevra Therapeutics (ZVRA), sold 91,000 shares in an open‑market transaction on Feb 2, 2026 for total proceeds of $853,425 (weighted average price $9.38). The Form 4 also reports derivative activity on Jan 31, 2026 (exercise/conversion of 233,334 derivative shares reported) and awards on Jan 29, 2026 (grants of 125,000 and 250,000 restricted stock units / derivative awards, and a stock option grant).
Key Details
- Primary sale: 91,000 shares disposed on 2026-02-02 at a weighted average price of $9.38; total proceeds reported $853,425. Trades executed at prices between $8.94 and $9.53 (weighted avg per filing).
- Derivative activity: 233,334 shares reported as an exercise/conversion on 2026-01-31 (the filing shows both an acquisition and a simultaneous disposal of 233,334 derivative shares at $0.00).
- Grants on 2026-01-29: 125,000 and 250,000 restricted stock units (RSUs) reported as awards (each RSU is a contingent right to one share per footnote).
- Option grant: Footnote indicates a stock option grant under the company’s equity plan (vesting in four equal annual installments per footnote).
- Vesting notes: Footnotes indicate RSUs vest and settle in installments (one‑third on 1/29/2027 and remaining in equal annual installments; another footnote states one‑third vested/settled on 1/31/2025 and 1/31/2026 with remaining on 1/31/2027).
- 10b5‑1 plan: Footnote shows a referenced 10b5‑1(c) plan adoption date of 03/21/2025.
- Filing detail: The sale was executed in multiple trades (F3) and the filer offers to provide granular trade information upon request. The provided filing did not list post‑transaction total shares beneficially owned.
Context
- Derivative explanation: The filing shows option/derivative exercises and RSU awards. When exercised/conversion entries are reported at $0 or as simultaneous acquisitions and disposals, that often reflects net share settlement, tax withholding, or internal settlement mechanics; the Form 4 here does not specify cash proceeds for those derivative disposals.
- Sale vs. purchase signal: The clear open‑market event is the Feb 2 sale for $853K. Sales are often routine (liquidity/tax/settlement) but do not necessarily signal management view of company prospects; RSU and option grants are compensation-related and not direct purchases of new economic exposure.
- Timeliness: No late‑filing flag was provided in the supplied data.
If you want, I can parse the likely post‑transaction ownership from the full Form 4 or request the detailed trade breakdown noted in the footnote.
Insider Transaction Report
Form 4
McFarlane Neil F.
DirectorPresident and CEO
Transactions
- Exercise/Conversion
Common Stock
[F1]2026-01-31+233,334→ 455,350 total - Sale
Common Stock
[F2][F3]2026-02-02$9.38/sh−91,000$853,425→ 364,350 total - Award
Restricted Stock Unit
[F1][F4]2026-01-29+125,000→ 125,000 total→ Common Stock (125,000 underlying) - Award
Stock Option (right to buy)
[F5]2026-01-29+250,000→ 250,000 totalExercise: $8.86Exp: 2036-01-28→ Common Stock (250,000 underlying) - Exercise/Conversion
Restricted Stock Unit
[F1][F6]2026-01-31−233,334→ 233,333 total→ Common Stock (233,334 underlying)
Footnotes (6)
- [F1]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- [F2]Adoption date of referenced 10b5-1(c) plan is: 03-21-2025.
- [F3]This transaction was executed in multiple trades at prices ranging from $8.94 to $9.53. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F4]The restricted stock units will vest and settle as to one third of the restricted stock units on January 29, 2027, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installments thereafter, subject in each case to the Reporting Person's continued service through such vesting date.
- [F5]Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan. The option will vest and become exercisable in four equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date.
- [F6]One third of the restricted stock units vested and settled on each of January 31, 2025 and January 31, 2026. The remaining one third of the shares will vest and settle on January 31, 2027, subject to the Reporting person's continued service through such vesting date.
Signature
/s/ Timothy J. Sangiovanni, Attorney-in-Fact for Neil F. McFarlane|2026-02-02